AADI News and Press, Aadi Bioscience Inc. From 03/04/24

2024-03-04 06:43:57 ET DENVER, Colo., Mar 04, 2024 ( 247marketnews.com )- Aadi Bioscience, Inc. (NASDAQ: AADI ) announced, in late Friday trading, that it published the long-term efficacy and safety results from its completed Phase 2 registrational AMPECT study of nab -sirolimus...

Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO® for the Treatment of Malignant PEComa PR Newswire After 3 years of follow-up in AMPECT trial, confirmed clinically meaningful overall response rate, including multiple p...

Aadi Bioscience to Present at the TD Cowen 44th Annual Healthcare Conference PR Newswire LOS ANGELES , Feb. 26, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies fo...

2024-02-12 17:30:02 ET More on Aadi Bioscience Aadi Bioscience: New Data Drives A Beaten Company Down, Not Really Justified Biggest stock movers today: Solar stocks, Intel, Scholastic and more. Aadi Bioscience stock plunges 57% on study data for anti-tumor drug ...

Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium PR Newswire Real-world genomic analysis highlights unmet medical need in GU cancer patients with TSC1/2 inactivating alterations ...

Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium PR Newswire - New real-world analysis highlights unmet medical need in GI cancer patients with TSC1/2 alterations- ...

2023-12-18 08:26:30 ET Losers: Chanson International Holding ( CHSN ) -88% . Inno Holdings ( INHD ) -85% . Maison Solutions ( MSS ) -84% issues statement regarding short attack on its securities . Aadi Bioscience ( AADI ) -56% . Sing...

2023-12-17 02:43:24 ET Summary Aadi Bioscience is a biotech company focused on a nanoliposomal encapsulation of the mTOR inhibitor sirolimus. Their drug, nab-sirolimus, has been approved for the treatment of PEComa, a rare soft tissue sarcoma. New findings from their tissue-ag...

2023-12-15 13:25:40 ET Gainers: Getaround ( GETR ) +116% . Battalion Oil Corp ( BATL ) +82% . La Rosa Holdings Corp. ( LRHC ) +45% . Verrica Pharmaceuticals ( VRCA ) +37% . Bruush Oral Care ( BRSH ) +36% . NCS Multistage Hold...

2023-12-15 10:00:27 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom For further details see: Myomo, Aileron...